View Financial HealthThis company is no longer activeThe company may no longer be operating, as it may be out of business. Find out why through their latest events.See Latest EventsDeep Medicine Acquisition 배당 및 자사주 매입배당 기준 점검 0/6Deep Medicine Acquisition 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률339.0%자사주 매입 수익률총 주주 수익률339.0%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공고 • Feb 01+ 1 more updateTrugolf, Inc. completed the acquisition of Deep Medicine Acquisition Corp. (NasdaqCM:DMAQ) from a group of shareholders in a reverse merger transaction.Trugolf, Inc. executed a non-binding letter of intent to acquire Deep Medicine Acquisition Corp. (NasdaqCM:DMAQ) from a group of shareholders in a reverse merger transaction on January 25, 2023. Trugolf, Inc. entered a definitive merger agreement to acquire Deep Medicine Acquisition Corp. from a group of shareholders in a reverse merger transaction for approximately $130 million on March 31, 2023. As reported, TruGolf stockholders will receive consideration in the form of newly issued shares of common stock DMAQ, valued based on an aggregate implied enterprise value for TruGolf of $125 million, including up to approximately $45 million of contingent consideration, subject to customary adjustments for TruGolf’s closing working capital, cash and debt and any unpaid transaction expenses. At the closing of the Business Combination, TruGolf Stockholders will receive 8,000,000 shares of New TruGolf Common Stock. In addition, 4.5 million Deep Medicine Class A Shares (Earnout Shares) will be issued as additional consideration. Upon completion of the transaction, assuming no redemptions by DMAQ’s stockholders, the combined company is expected to have a total pro forma equity value of approximately $134.1 million. As a result of the merger, TruGolf, Inc. will become a public company to further advance its software business and increase manufacturing and sales of its golf simulator technology in the United States and internationally. Upon completion of the transaction, the combined company is expected to be renamed TruGolf Holdings, Inc. and will be listed on the Nasdaq Stock Market and its shares of common stock will trade under the trading symbol “TRUG”. Christopher Jones, Chief Executive Officer and Chairman of TruGolf, and the existing management team will lead the merged company. In the event the Merger Agreement is terminated by TruGolf, TruGolf will pay a termination fee equal to $250,000 plus an amount equal to the aggregate DMAQ transaction expenses actually and directly incurred by DMAQ, provided that the Termination Fee shall not exceed $750,000.The closing of the transaction is subject to approval by TruGolf’s stockholders and DMAQ’s stockholders; any waiting period (and any extension thereof) applicable to the consummation of the Merger Agreement under any antitrust laws shall have expired or been terminated; the receipt of all consents required to be obtained from or made with any governmental authority; upon the closing, DMAQ having cash and cash equivalents equal to at least $10 million; the members of the New TruGolf Board having been elected or appointed as of the Closing consistent with the requirements of the Merger Agreement; the Registration Statement of which proxy statement/prospectus forms a part having been declared effective by the SEC; each Lock-Up Agreement and Non-Competition Agreement, Registration rights agreement having been duly executed; DMAQ having received new employment agreements for certain specified persons and is subject to other customary closing conditions. The boards of directors of DMAQ and TruGolf both unanimously approved the proposed transaction. DMAQ Board recommended that shareholders vote for the merger. The registration statement was declared effective on December 27, 2023. It is currently anticipated that the transaction will close by the end of the third quarter of 2023. The outside date for the business combination is January 29, 2024. As of January 12, 2024, the transaction is expected to close by the end of January 2024. The proceeds from the transaction will enhance TruGolf’s production capacity, new product research and development, working capital and expansion. As of January 19, 2024, DMAQ stockholders approved the transaction.Nicholas M. Tipsord, Olga Bogush, Amy (Salomon) McFarland, Juliana I. Haydoutova and Cavas S. Pavri of ArentFox Schiff LLP is serving as legal advisors to TruGolf. Barry I. Grossman and Lloyd N. Steele of Ellenoff Grossman & Schole, LLP are serving as legal advisors to DMAQ and Bright Vision Sponsor LLC. Ellenoff Grossman & Schole, LLP also provided due diligence services to DMAQ. Stanton Park Advisors, LLC acted as financial advisor and rendered fairness opinion to the DMAQ Board. American Stock Transfer & Trust Company, LLC acted as the transfer agent for Deep Medicine’s securities. Advantage Proxy, Inc. acted as proxy solicitor to DMAQ for an approximate fee of $10,000, plus disbursements. Stanton Park received a fee of $15,000 for its opinion, no portion of which was contingent upon the completion of the Business Combination. Arthur S. Marcus and Matthew Siracusa of Sichenzia Ross Ference LLP acted as legal advisors to Deep Medicine Acquisition.Trugolf, Inc. completed the acquisition of Deep Medicine Acquisition Corp. (NasdaqCM:DMAQ) from a group of shareholders in a reverse merger transaction on January 31, 2024. In connection with the completion of the Business Combination, TruGolf’s Class A common stock will begin trading on the Nasdaq Stock Market (“Nasdaq”) under the ticker symbol “TRUG”, on February 1, 2024. TruGolf’s current management team will continue to lead the combined company following the closing. I-Bankers Securities, Inc. acted as sole bookrunner for the DMAQ IPO and served as financial advisor to DMAQ. Sichenzia Ross Ference Carmel LLP served as counsel to TruGolf.공고 • Jan 27Deep Medicine Acquisition Corp. Approves the Election of DirectorsOn January 19, 2024, Deep Medicine Acquisition Corp. held a special meeting of its stockholders approved the election of Christopher Jones, Shaun Limbers, AJ Redmer and Riley Russell as Directors.공고 • Feb 18Deep Medicine Acquisition Announces Listing Transfer to the Nasdaq Capital MarketDeep Medicine Acquisition Corp. (the “Company”) announced that it has received approval from the Nasdaq Stock Market (“Nasdaq”) to transfer the listing of its securities from the Nasdaq Global Market to the Nasdaq Capital Market. The Company's Class A common stock and rights will continue to trade under the symbol “DMAQ” and “DMAQR,” respectively and trading of its Class A common stock and rights will be unaffected by this transfer. This transfer will be effective as of the opening of business on February 17, 2023. As previously disclosed, the Company received a letter from Nasdaq on January 22, 2023 indicating that the Company, following the stockholder redemptions at its last stockholder meeting, is not in compliance with Listing Rule 5450(b)(2), due to the Company’s failure to meet the minimum 1,100,000 publicly held shares requirement for continued listing on the Nasdaq Global Market. Upon the transfer of listing of the Company's securities on the Nasdaq Capital Market on February 17, 2023, such deficiency would be resolved.공고 • Jan 28Deep Medicine Acquisition Receives Non-Compliance Notice Form NasdaqOn January 22, 2023, Deep Medicine Acquisition Corp. received a written notice (the Notice") from the Listing Qualifications Department of The Nasdaq Stock Market (Nasdaq") indicating that, following the stockholder redemptions at the Company's last stockholder meeting, the Company is not in compliance with Listing Rule 5450(b)(2), due to the Company's failure to meet the minimum 1,100,000 publicly held shares requirement for continued listing on the Nasdaq Global Market. The Notice is only a notification of deficiency, not of imminent delisting, and has no current effect on the listing or trading of the Company's securities on the Nasdaq Global Market. The Notice states that the Company has until March 9, 2023 to submit a plan to regain compliance with Listing Rule 5450(b)(2). The Company is exploring all options to regain compliance with Listing Rule 5450(b)(2). The Company intends to submit a plan to regain compliance with Listing Rule 5450(b)(2) within the required timeframe. If Nasdaq accepts the Company's plan, Nasdaq may grant the Company an extension of up to 180 calendar days from the date of the Notice to evidence compliance with Listing Rule 5450(b)(2). If Nasdaq does not accept the Company's plan, the Company will have the opportunity to appeal the decision in front of a Nasdaq Hearings Panel.공고 • Nov 23Deep Medicine Acquisition Corp., Annual General Meeting, Dec 23, 2022Deep Medicine Acquisition Corp., Annual General Meeting, Dec 23, 2022.공고 • Oct 25Deep Medicine Acquisition Corp. Appoints John Chiang as Member to its Board of DirectorsDeep Medicine Acquisition Corp. announced the appointment of Mr. John Chiang as a member to its board of directors, effective October 15, 2022. Mr. Chiang has been serving as a member of the board of directors of Apollo Medical Holdings Inc. since January 2019 and on the corporate advisory boards of Pasadena Private Lending, LLC since February 2019, Adept Urban since January 2021, and Calyx Peak Companies since February 2019. From January 2015 to January 2019, Mr. Chiang served as the California State Treasurer, where he oversaw financial transactions, investments and the sale of bonds. Prior to that, Mr. Chiang served as California State Controller from January 2007 to January 2015.공고 • Jul 14Chijet Inc. entered into a definitive business combination agreement to acquire Deep Medicine Acquisition Corp. (NasdaqGM:DMAQ) in a reverse merger transaction.Chijet Inc. entered into a definitive business combination agreement to acquire Deep Medicine Acquisition Corp. (NasdaqGM:DMAQ) in a reverse merger transaction on July 12, 2022. Business combination agreement with Deep Medicine Acquisition Corp. values Chijet’s operating companies at $2.55 billion (based on 100% ownership). In the proposed transaction, both Chijet and DMAQ will be acquired by a newly-formed holding company named Chijet Motor Company, Inc. (“Pubco”), which is expected to be listed on the Nasdaq Stock Market (“Nasdaq”). Each of the DMAQ's issued and outstanding shares of Class A Common Stock will be cancelled in exchange for the right of the holder thereof to receive one ordinary share, par value $0.0001 per share, of Pubco. Hongwei Mu, Chairman of Chijet, and the existing leadership team will lead the combined company. The boards of directors of DMAQ and Chijet have unanimously approved the proposed transaction. Its closing is subject to approval by DMAQ stockholders, completion of DMAQ’s satisfactory due diligence review of Chijet within 60 days of entering into the business combination agreement and is subject to other customary closing conditions, including the U.S. Securities and Exchange Commission (“SEC”) declaring Pubco’s registration statement effective and the expiration of the applicable HSR Act waiting period. It is currently expected that the transaction will close by the end of the fourth quarter of 2022, assuming such closing conditions are met.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 DMAQ 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: DMAQ 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Deep Medicine Acquisition 배당 수익률 vs 시장DMAQ의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (DMAQ)n/a시장 하위 25% (US)1.3%시장 상위 25% (US)4.0%업계 평균 (Capital Markets)1.9%분석가 예측 (DMAQ) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 DMAQ 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 DMAQ 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 DMAQ 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: DMAQ 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YUS 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2024/01/31 18:58종가2024/01/31 00:00수익2023/09/30연간 수익2023/03/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Deep Medicine Acquisition Corp.는 0명의 분석가가 다루고 있습니다. 이 중 명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공고 • Feb 01+ 1 more updateTrugolf, Inc. completed the acquisition of Deep Medicine Acquisition Corp. (NasdaqCM:DMAQ) from a group of shareholders in a reverse merger transaction.Trugolf, Inc. executed a non-binding letter of intent to acquire Deep Medicine Acquisition Corp. (NasdaqCM:DMAQ) from a group of shareholders in a reverse merger transaction on January 25, 2023. Trugolf, Inc. entered a definitive merger agreement to acquire Deep Medicine Acquisition Corp. from a group of shareholders in a reverse merger transaction for approximately $130 million on March 31, 2023. As reported, TruGolf stockholders will receive consideration in the form of newly issued shares of common stock DMAQ, valued based on an aggregate implied enterprise value for TruGolf of $125 million, including up to approximately $45 million of contingent consideration, subject to customary adjustments for TruGolf’s closing working capital, cash and debt and any unpaid transaction expenses. At the closing of the Business Combination, TruGolf Stockholders will receive 8,000,000 shares of New TruGolf Common Stock. In addition, 4.5 million Deep Medicine Class A Shares (Earnout Shares) will be issued as additional consideration. Upon completion of the transaction, assuming no redemptions by DMAQ’s stockholders, the combined company is expected to have a total pro forma equity value of approximately $134.1 million. As a result of the merger, TruGolf, Inc. will become a public company to further advance its software business and increase manufacturing and sales of its golf simulator technology in the United States and internationally. Upon completion of the transaction, the combined company is expected to be renamed TruGolf Holdings, Inc. and will be listed on the Nasdaq Stock Market and its shares of common stock will trade under the trading symbol “TRUG”. Christopher Jones, Chief Executive Officer and Chairman of TruGolf, and the existing management team will lead the merged company. In the event the Merger Agreement is terminated by TruGolf, TruGolf will pay a termination fee equal to $250,000 plus an amount equal to the aggregate DMAQ transaction expenses actually and directly incurred by DMAQ, provided that the Termination Fee shall not exceed $750,000.The closing of the transaction is subject to approval by TruGolf’s stockholders and DMAQ’s stockholders; any waiting period (and any extension thereof) applicable to the consummation of the Merger Agreement under any antitrust laws shall have expired or been terminated; the receipt of all consents required to be obtained from or made with any governmental authority; upon the closing, DMAQ having cash and cash equivalents equal to at least $10 million; the members of the New TruGolf Board having been elected or appointed as of the Closing consistent with the requirements of the Merger Agreement; the Registration Statement of which proxy statement/prospectus forms a part having been declared effective by the SEC; each Lock-Up Agreement and Non-Competition Agreement, Registration rights agreement having been duly executed; DMAQ having received new employment agreements for certain specified persons and is subject to other customary closing conditions. The boards of directors of DMAQ and TruGolf both unanimously approved the proposed transaction. DMAQ Board recommended that shareholders vote for the merger. The registration statement was declared effective on December 27, 2023. It is currently anticipated that the transaction will close by the end of the third quarter of 2023. The outside date for the business combination is January 29, 2024. As of January 12, 2024, the transaction is expected to close by the end of January 2024. The proceeds from the transaction will enhance TruGolf’s production capacity, new product research and development, working capital and expansion. As of January 19, 2024, DMAQ stockholders approved the transaction.Nicholas M. Tipsord, Olga Bogush, Amy (Salomon) McFarland, Juliana I. Haydoutova and Cavas S. Pavri of ArentFox Schiff LLP is serving as legal advisors to TruGolf. Barry I. Grossman and Lloyd N. Steele of Ellenoff Grossman & Schole, LLP are serving as legal advisors to DMAQ and Bright Vision Sponsor LLC. Ellenoff Grossman & Schole, LLP also provided due diligence services to DMAQ. Stanton Park Advisors, LLC acted as financial advisor and rendered fairness opinion to the DMAQ Board. American Stock Transfer & Trust Company, LLC acted as the transfer agent for Deep Medicine’s securities. Advantage Proxy, Inc. acted as proxy solicitor to DMAQ for an approximate fee of $10,000, plus disbursements. Stanton Park received a fee of $15,000 for its opinion, no portion of which was contingent upon the completion of the Business Combination. Arthur S. Marcus and Matthew Siracusa of Sichenzia Ross Ference LLP acted as legal advisors to Deep Medicine Acquisition.Trugolf, Inc. completed the acquisition of Deep Medicine Acquisition Corp. (NasdaqCM:DMAQ) from a group of shareholders in a reverse merger transaction on January 31, 2024. In connection with the completion of the Business Combination, TruGolf’s Class A common stock will begin trading on the Nasdaq Stock Market (“Nasdaq”) under the ticker symbol “TRUG”, on February 1, 2024. TruGolf’s current management team will continue to lead the combined company following the closing. I-Bankers Securities, Inc. acted as sole bookrunner for the DMAQ IPO and served as financial advisor to DMAQ. Sichenzia Ross Ference Carmel LLP served as counsel to TruGolf.
공고 • Jan 27Deep Medicine Acquisition Corp. Approves the Election of DirectorsOn January 19, 2024, Deep Medicine Acquisition Corp. held a special meeting of its stockholders approved the election of Christopher Jones, Shaun Limbers, AJ Redmer and Riley Russell as Directors.
공고 • Feb 18Deep Medicine Acquisition Announces Listing Transfer to the Nasdaq Capital MarketDeep Medicine Acquisition Corp. (the “Company”) announced that it has received approval from the Nasdaq Stock Market (“Nasdaq”) to transfer the listing of its securities from the Nasdaq Global Market to the Nasdaq Capital Market. The Company's Class A common stock and rights will continue to trade under the symbol “DMAQ” and “DMAQR,” respectively and trading of its Class A common stock and rights will be unaffected by this transfer. This transfer will be effective as of the opening of business on February 17, 2023. As previously disclosed, the Company received a letter from Nasdaq on January 22, 2023 indicating that the Company, following the stockholder redemptions at its last stockholder meeting, is not in compliance with Listing Rule 5450(b)(2), due to the Company’s failure to meet the minimum 1,100,000 publicly held shares requirement for continued listing on the Nasdaq Global Market. Upon the transfer of listing of the Company's securities on the Nasdaq Capital Market on February 17, 2023, such deficiency would be resolved.
공고 • Jan 28Deep Medicine Acquisition Receives Non-Compliance Notice Form NasdaqOn January 22, 2023, Deep Medicine Acquisition Corp. received a written notice (the Notice") from the Listing Qualifications Department of The Nasdaq Stock Market (Nasdaq") indicating that, following the stockholder redemptions at the Company's last stockholder meeting, the Company is not in compliance with Listing Rule 5450(b)(2), due to the Company's failure to meet the minimum 1,100,000 publicly held shares requirement for continued listing on the Nasdaq Global Market. The Notice is only a notification of deficiency, not of imminent delisting, and has no current effect on the listing or trading of the Company's securities on the Nasdaq Global Market. The Notice states that the Company has until March 9, 2023 to submit a plan to regain compliance with Listing Rule 5450(b)(2). The Company is exploring all options to regain compliance with Listing Rule 5450(b)(2). The Company intends to submit a plan to regain compliance with Listing Rule 5450(b)(2) within the required timeframe. If Nasdaq accepts the Company's plan, Nasdaq may grant the Company an extension of up to 180 calendar days from the date of the Notice to evidence compliance with Listing Rule 5450(b)(2). If Nasdaq does not accept the Company's plan, the Company will have the opportunity to appeal the decision in front of a Nasdaq Hearings Panel.
공고 • Nov 23Deep Medicine Acquisition Corp., Annual General Meeting, Dec 23, 2022Deep Medicine Acquisition Corp., Annual General Meeting, Dec 23, 2022.
공고 • Oct 25Deep Medicine Acquisition Corp. Appoints John Chiang as Member to its Board of DirectorsDeep Medicine Acquisition Corp. announced the appointment of Mr. John Chiang as a member to its board of directors, effective October 15, 2022. Mr. Chiang has been serving as a member of the board of directors of Apollo Medical Holdings Inc. since January 2019 and on the corporate advisory boards of Pasadena Private Lending, LLC since February 2019, Adept Urban since January 2021, and Calyx Peak Companies since February 2019. From January 2015 to January 2019, Mr. Chiang served as the California State Treasurer, where he oversaw financial transactions, investments and the sale of bonds. Prior to that, Mr. Chiang served as California State Controller from January 2007 to January 2015.
공고 • Jul 14Chijet Inc. entered into a definitive business combination agreement to acquire Deep Medicine Acquisition Corp. (NasdaqGM:DMAQ) in a reverse merger transaction.Chijet Inc. entered into a definitive business combination agreement to acquire Deep Medicine Acquisition Corp. (NasdaqGM:DMAQ) in a reverse merger transaction on July 12, 2022. Business combination agreement with Deep Medicine Acquisition Corp. values Chijet’s operating companies at $2.55 billion (based on 100% ownership). In the proposed transaction, both Chijet and DMAQ will be acquired by a newly-formed holding company named Chijet Motor Company, Inc. (“Pubco”), which is expected to be listed on the Nasdaq Stock Market (“Nasdaq”). Each of the DMAQ's issued and outstanding shares of Class A Common Stock will be cancelled in exchange for the right of the holder thereof to receive one ordinary share, par value $0.0001 per share, of Pubco. Hongwei Mu, Chairman of Chijet, and the existing leadership team will lead the combined company. The boards of directors of DMAQ and Chijet have unanimously approved the proposed transaction. Its closing is subject to approval by DMAQ stockholders, completion of DMAQ’s satisfactory due diligence review of Chijet within 60 days of entering into the business combination agreement and is subject to other customary closing conditions, including the U.S. Securities and Exchange Commission (“SEC”) declaring Pubco’s registration statement effective and the expiration of the applicable HSR Act waiting period. It is currently expected that the transaction will close by the end of the fourth quarter of 2022, assuming such closing conditions are met.